WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Hoth Therapeutics Inc - Growth / Value Index


HOTH - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.434 indicating that it is undervalued.
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.595 -0.418 -236.44 %
Price to Book 0.468 0.456 65.40 % 0.663
Price to Sales 76.96 0 0 %
Enterprise Value to EBITDA Multiple 0.463 0.545 20.17 %


HOTH - Profitability Highlights

Profitability Analysis

   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -78.64 -109.15 50.84 % -26.05
Return On Asset -69.42 -101.07 39.92 % -24.03
Net Profit Margin -12937.39 0 0 % 0
Operating Profit Margin -12687.00 0 0 % 0
EBITDA Margin -12687.00 0 0 % 0


Highlights
Market Cap5768.78 K
Enterprise Value-3494.73 K
Price/Book TTM0.468
Outstanding Share4888.80 K
Float/ Outstanding Share79.79%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score-5.11
Sloan Ratio-0.178
Peter Lynch Fair Value0


HOTH - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 59538.00 % 100.00 %
Gross Profit 15120.00 100.00 % 100.00 %
EBITDA -7553.59 K 13.05 % 20.99 %
Net Profit -7702.66 K 15.38 % 19.89 %
EPS -1.98 70.28 % NA


HOTH - Stability Highlights

Stability Analysis

   Cash ratio of 13.69
   Altman Z Score of -5.11 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0033 0 % 0.0037
Cash Ratio 13.69 186.25 %
Quick Ratio 0 0 % 12.28
Shareholders Equity 92.59 22.20 %
Debt to EBITDA -0.0030 0 %


Historical Valuation Ratios of Hoth Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Hoth Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Hoth Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Hoth Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)